Buchumschlag

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease. Authors' Reply

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Cristina Rubín de Célix, María Chaparro, Javier P. Gisbert
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: Managing the Moving Target—Dose Adjustments in Inflammatory Bowel Disease
von: Nicholas Clark, et al.
Veröffentlicht: (2025)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
von: María Chaparro, et al.
Veröffentlicht: (2024)

Editorial: Allostatic Load and Inflammatory Bowel Disease. Authors' Reply
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Editorial: Can We Prevent Inflammatory Bowel Disease? Authors' Reply
von: Fai Fai Ho, et al.
Veröffentlicht: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease: Authors' Reply
von: Suprabhat Giri, et al.
Veröffentlicht: (2025)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease? Authors' Reply
von: Bharati Kochar, et al.
Veröffentlicht: (2025)

Editorial: Optimal Treatment for Older Patients With Inflammatory Bowel Disease: How to Detect and Manage Frailty? Authors' Reply
von: A. B. Fons, et al.
Veröffentlicht: (2026)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues. Authors' Reply
von: Jessica A. Fitzpatrick, et al.
Veröffentlicht: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
von: Aurelien Amiot, et al.
Veröffentlicht: (2025)

Editorial: H. pylori Treatment—Old Ingredients in New Effective Regimens. Authors' Reply
von: Olga P. Nyssen, et al.
Veröffentlicht: (2025)

Editorial: Sequencing rescue therapy for acute severe ulcerative colitis—Ready for revision? Authors' reply
von: María José García, et al.
Veröffentlicht: (2024)

Editorial: Mitigating the Risk of Adverse Pregnancy Outcomes in Women With Inflammatory Bowel Disease and Chronic Liver Disease—Authors' Reply
von: Jessica D. Lee, et al.
Veröffentlicht: (2025)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination. Authors' Reply
von: Anupam Kumar Singh, et al.
Veröffentlicht: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
von: Isabel Carbery, et al.
Veröffentlicht: (2024)

Editorial: JAK to JAK—Navigating Intra‐Class JAK Inhibitor Switching in Inflammatory Bowel Disease. Authors' Reply
von: Mathieu Uzzan, et al.
Veröffentlicht: (2025)

Letter: Incremental Value and Outcome Modelling in Frailty Assessment for Older Patients with Inflammatory Bowel Disease. Author's Reply
von: A. B. Fons, et al.
Veröffentlicht: (2026)

Letter: Third‐line therapy in acute severe ulcerative colitis, exploring the uncertainty and unanswered questions—Authors' reply
von: María José García, et al.
Veröffentlicht: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Letter: Are All Extra‐Digestive Cancer Signals in Inflammatory Bowel Disease Telling the Same Story? Authors' Reply
von: Sanjay K. Murthy
Veröffentlicht: (2026)

Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
von: Uma Mahadevan, et al.
Veröffentlicht: (2025)

Editorial: High‐Grade Dysplasia in Colonic Inflammatory Bowel Disease Is Associated With a High Risk of Synchronous or Metachronous Colorectal Cancer—Authors' Reply
von: Monica E. W. Derks, et al.
Veröffentlicht: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
von: José Luis Rueda García, et al.
Veröffentlicht: (2026)

Editorial: Allostatic Load and Inflammatory Bowel Disease
von: Jeli Mendoza, et al.
Veröffentlicht: (2024)

Editorial: Are Antidepressant Medications Safe in Inflammatory Bowel Disease?
von: Matthew D. Coates, et al.
Veröffentlicht: (2025)

Editorial: The Hidden Burden—Stigmatisation in Inflammatory Bowel Disease
von: Marco Vincenzo Lenti, et al.
Veröffentlicht: (2025)

Editorial: Can We Prevent Inflammatory Bowel Disease?
von: Agnes Hiu Yan Ho, et al.
Veröffentlicht: (2025)

Long‐Term Outcomes Following Withdrawal of Anti‐Tumour Necrosis Factor Treatment in Inflammatory Bowel Disease Patients in Remission: The Exit Long‐Term Study of GETECCU
von: María José Casanova, et al.
Veröffentlicht: (2025)

Editorial: UDCA Dosing in PBC—Between Guideline Adherence and Clinical Reality: Authors' Reply
von: Ellen Werner, et al.
Veröffentlicht: (2026)

Clinical Trial: Immunogenicity of Double‐Dose Versus Standard‐Dose of Hepatitis B Virus Vaccine in Inflammatory Bowel Disease
von: Anupam Kumar Singh, et al.
Veröffentlicht: (2025)

Editorial: Inflammatory Bowel Disease and Dietary Emulsifiers—A Conundrum That Continues
von: Stephanie Gold, et al.
Veröffentlicht: (2025)

Letter: Early Inflammatory Benefit Is Not Yet Equivalent to Durable Surgical Advantage After Colectomy in Colonic Crohn's Disease. Authors' Reply
von: José Luis Rueda García, et al.
Veröffentlicht: (2026)

Meta‐Analysis: Improvement of Bowel Urgency With Advanced Therapies for Inflammatory Bowel Disease
von: Purab Patel, et al.
Veröffentlicht: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet?
von: Joyce Wing Yan Mak
Veröffentlicht: (2025)

Letter: Statins for Cirrhosis: Are we Ready to Move From Cardiovascular Prophylaxis to Portal Pressure Management? Authors' Reply
von: Bernardo de Faria Moraes, et al.
Veröffentlicht: (2026)

Editorial: Targeting Urgency in IBD —A Historical Divide. Authors' Reply
von: Parul Tandon, et al.
Veröffentlicht: (2025)

Letter: Optimising Hepatitis B Vaccination in Inflammatory Bowel Disease – Expanding Strategies Beyond Double‐Dose Recombinant Vaccination
von: Yash Hegde, et al.
Veröffentlicht: (2026)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
von: Federica Tavaglione, et al.
Veröffentlicht: (2025)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2025)

Systematic Review: Stigma Associated With Inflammatory Bowel Disease
von: Suprabhat Giri, et al.
Veröffentlicht: (2025)